Does Johnson & Johnson Have a Growth Problem?

This episode of The Motley Fool's Market Checkup is dedicated to the world's largest health-care conglomerate, Johnson & Johnson . Market Checkup gives a full examination of J&J's second-quarter results and takes a closer look at the company's three main business segments: medical devices and diagnostics, pharmaceuticals, and consumer.

In this video, health-care analysts David Williamson and Max Macaluso drill down on medical devices and diagnostics, J&J's largest segment. Watch and find out why the company's reported growth may not be as strong as it appears, and why this division may get a name change in the not too distant future.

One of the best parts of owning Big Pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

The article Does Johnson & Johnson Have a Growth Problem? originally appeared on Fool.com.

David Williamson owns shares of Pfizer, Johnson & Johnson, Abbott Labs, and AbbVie. Follow David on Twitter: @MotleyDavid. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.